DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
SoloStar - 1 George Frey - 1 GoodRx - 1 Eli Lilly - 1 Khushi - 1 Shweta Agarwal - 1
Top related locs:
Provo , Utah U.S Lilly Bengaluru
Top related orgs:
Sanofi Pharmaceutical - 1 REUTERS - 1 Sanofi - 1 U.S . - 1 Novo Nordisk - 1 Novo - 1 American Diabetes Association - 1 Thomson - 1

Search resuls for: "SoloStar"


3 mentions found


☆ GoodRx to offer Sanofi's insulin injection for only $35
  + stars: | 2023-10-19 | by ( ) www.reuters.com   time to read: +1 min
A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo, Utah, U.S. January 9, 2020. This collaboration comes after Novo Nordisk (NOVOb.CO) , Eli Lilly (LLY.N) and Sanofi pledged in March to lower the list prices of many of their insulin products by 70%-78% later in the year or in 2024. Americans with insurance typically pay a fraction of the list prices for prescription drugs, but uninsured people sometimes have to pay the full price, forcing some to ration or skip taking their medicine. About 8.4 million of the 37 million people with diabetes in the U.S. use insulin, according to the American Diabetes Association. Reporting by Khushi Mandowara in Bengaluru; Editing by Shweta AgarwalOur Standards: The Thomson Reuters Trust Principles.
Persons: SoloStar, George Frey, GoodRx, Eli Lilly, Khushi, Shweta Agarwal Organizations: Sanofi Pharmaceutical, REUTERS, Sanofi, U.S ., Novo Nordisk, Novo, American Diabetes Association, Thomson Locations: Provo , Utah, U.S, Lilly, Bengaluru
☆ Facing political pressure, Sanofi follows Eli Lilly and Novo Nordisk in slashing insulin prices
  + stars: | 2023-03-16 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Sanofi already offers a $35 monthly cap on insulin for uninsured diabetes patients. The company is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts for the lifesaving hormone. Eli Lilly and Novo Nordisk made similar sweeping cuts earlier this month after years of political pressure and public outrage over the high costs of diabetes care. President Joe Biden's Inflation Reduction Act capped monthly insulin costs for Medicare beneficiaries at $35, but it did not provide protection to diabetes patients who are covered by private insurance. Approximately 8.4 million diabetes patients rely on insulin, the American Diabetes Association said.
☆ Sanofi to cut US price of its most-prescribed insulin by 78%
  + stars: | 2023-03-16 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +3 min
In addition to Lantus, Sanofi said it will cut by 70% the list price for its fast-acting insulin, Apidra. The branded list price of Lantus is $438.07 for the pre-filled pens and $292.07 for a 10 ml vial. Rival Novo Nordisk on Tuesday said it would cut U.S. list prices for several insulin products by up to 75% next year. That followed Lilly's March 2 decision to cut list prices by 70% for Humalog and Humulin, its most commonly prescribed insulin products. Most Americans with insurance do not regularly pay list price for insulin, but they may have an insurance co-pay based on the drug's list price or pay full price up to a certain amount of money spent.
0 next >>
Total: 3